AveXis (AVXS) Rating Reiterated by BMO Capital Markets
Several other brokerages also recently weighed in on AVXS. Citigroup set a $132.00 target price on AveXis and gave the company a buy rating in a research note on Friday, January 5th. Canaccord Genuity set a $110.00 target price on AveXis and gave the company a hold rating in a research note on Wednesday, December 20th. BidaskClub downgraded AveXis from a hold rating to a sell rating in a research note on Thursday, December 14th. Bank of America decreased their target price on AveXis from $115.00 to $112.00 and set a buy rating for the company in a research note on Friday, November 10th. Finally, Morgan Stanley set a $120.00 target price on AveXis and gave the company a buy rating in a research note on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $111.67.
Shares of AveXis (NASDAQ AVXS) traded up $1.16 during trading hours on Monday, reaching $117.50. The company had a trading volume of 624,968 shares, compared to its average volume of 476,200. AveXis has a 1 year low of $50.56 and a 1 year high of $119.00. The company has a market cap of $3,720.00 and a P/E ratio of -21.06.
In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total transaction of $1,646,250.00. Following the completion of the transaction, the insider now owns 1,808,386 shares in the company, valued at approximately $198,470,363.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total value of $180,242.80. Following the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $180,242.80. The disclosure for this sale can be found here. Insiders have sold a total of 52,340 shares of company stock valued at $5,318,845 in the last 90 days. 18.60% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its position in shares of AveXis by 19.6% during the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after buying an additional 523 shares during the period. Parametric Portfolio Associates LLC increased its holdings in AveXis by 2.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock valued at $1,721,000 after purchasing an additional 598 shares in the last quarter. ProShare Advisors LLC increased its holdings in AveXis by 6.4% during the 2nd quarter. ProShare Advisors LLC now owns 16,427 shares of the company’s stock valued at $1,350,000 after purchasing an additional 985 shares in the last quarter. SG Americas Securities LLC increased its holdings in AveXis by 28.2% during the 2nd quarter. SG Americas Securities LLC now owns 5,111 shares of the company’s stock valued at $420,000 after purchasing an additional 1,124 shares in the last quarter. Finally, Strs Ohio acquired a new stake in AveXis during the 3rd quarter valued at $116,000. Institutional investors and hedge funds own 92.88% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AveXis (AVXS) Rating Reiterated by BMO Capital Markets” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/12/avexis-avxs-rating-reiterated-by-bmo-capital-markets.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.